Keytruda Qlex Injection, Solution
Product Images NDC 0006-5083

Product Visual Gallery

This gallery contains 44 technical images submitted to the FDA as part of the official labeling for Keytruda Qlex (NDC 0006-5083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Keytruda Qlex 01)

A Kaplan-Meier survival curve chart depicting overall survival percentage over time in months for three treatment arms: IV Pembrolizumab 10 mg/kg every 2 weeks, IV Pembrolizumab 10 mg/kg every 3 weeks, and Ipilimumab. The chart includes a number at risk table for each treatment arm over time.*

FDA Label Image

Figure 2 (Keytruda Qlex 02)

A Kaplan-Meier survival curve chart showing progression-free survival (%) over time (months) for three treatment arms: IV Pembrolizumab 10 mg/kg every 3 weeks, IV Pembrolizumab 2 mg/kg every 3 weeks, and Chemotherapy. The chart includes a table of number at risk for each treatment group at various time points.*

FDA Label Image

Figure 3 (Keytruda Qlex 03)

A Kaplan-Meier curve showing recurrence-free survival (%) over time in months for two treatment arms: IV pembrolizumab and placebo. The graph tracks patient risk numbers below the x-axis, illustrating survival trends for each group up to 27 months.*

FDA Label Image

Figure 4 (Keytruda Qlex 04)

A Kaplan-Meier survival curve chart showing recurrence-free survival (%) over 24 months comparing two treatment arms: IV Pembrolizumab (solid black line) and Placebo (dashed gray line). The chart includes a risk table with the number of patients at risk at various time points for each treatment arm.*

FDA Label Image

Figure 5 (Keytruda Qlex 05)

A Kaplan-Meier plot showing overall survival percentage over time in months for patients treated with intravenous pembrolizumab versus a control group. The graph includes a table indicating the number of patients at risk for each group at various time points up to 42 months. The plot illustrates better survival outcomes in the pembrolizumab treatment arm compared to the control.*

FDA Label Image

Figure 6 (Keytruda Qlex 06)

A Kaplan-Meier survival curve chart comparing overall survival (%) over time in months between two groups: IV Pembrolizumab treatment arm (black line) and Control (gray line). The chart includes a risk table below showing the number of patients at risk for each group over the time points.*

FDA Label Image

Figure 7 (Keytruda Qlex 07)

A Kaplan-Meier overall survival curve comparing IV pembrolizumab and chemotherapy treatment arms over time in months, showing percentage survival on the y-axis. The graph includes a risk table indicating the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 8 (Keytruda Qlex 08)

A Kaplan-Meier survival curve chart depicting overall survival percentage over time in months for two treatment arms: IV pembrolizumab and chemotherapy. The chart shows higher overall survival rates for IV pembrolizumab compared to chemotherapy across the time period of up to 33 months, with patient numbers at risk listed below the x-axis.*

FDA Label Image

Figure 9 (Keytruda Qlex 09)

A Kaplan-Meier survival curve chart depicting overall survival percentage over time in months for three treatment arms: IV Pembrolizumab 2 mg/kg, IV Pembrolizumab 10 mg/kg, and Docetaxel. The chart includes survival curves for each treatment and a table of the number of patients at risk at various time points up to 24 months.*

FDA Label Image

Figure 10 (Keytruda Qlex 10)

A Kaplan-Meier survival curve chart showing overall survival percentage on the y-axis and time in months on the x-axis. It compares two treatment arms: IV Pembrolizumab and a control group, with IV Pembrolizumab showing higher overall survival over time. The number at risk for each group is listed below the x-axis at various time intervals up to 60 months.*

FDA Label Image

Figure 11 (Keytruda Qlex 11)

A Kaplan-Meier curve showing disease-free survival (%) over time in months for two treatment arms: IV Pembrolizumab and Placebo. The chart includes survival data points with censored events and a table of numbers at risk at various time intervals up to 60 months.*

FDA Label Image

Figure 12 (Keytruda Qlex 12)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months for two groups: IV Pembrolizumab plus Chemotherapy (solid line) and a Control group (dashed line). The x-axis represents time in months, and the y-axis represents overall survival percentage. The chart includes a number-at-risk table below indicating patient counts for each group over time.*

FDA Label Image

Figure 13 (Keytruda Qlex 14)

A Kaplan-Meier survival curve chart depicting Overall Survival (%) versus Time in Months for two treatment arms: Pembrolizumab plus chemotherapy (solid line) and standard treatment (dashed line). The chart includes a 'Number at Risk' table below, showing patient counts at various time points for each treatment group.*

FDA Label Image

Figure 14 (Keytruda Qlex 15)

A Kaplan-Meier overall survival curve comparing IV Pembrolizumab and Standard treatment arms over time in months. The y-axis shows overall survival percentage and the x-axis shows time in months, with survival declining over time for both groups. A table below the graph lists the number of patients at risk at various time points for each treatment arm.*

FDA Label Image

Figure 15 (Keytruda Qlex 16)

A survival curve chart comparing overall survival (%) over time in months for two treatment arms: IV Pembrolizumab + EV (solid black line) and Chemotherapy (dashed gray line). The chart includes a number at risk table below.*

FDA Label Image

Figure 16 (Keytruda Qlex 17)

A Kaplan-Meier curve chart depicting progression-free survival (%) over time (months) for two treatment arms: IV Pembrolizumab + EV (solid line) and Chemotherapy (dashed line). The chart shows higher survival rates over time for the IV Pembrolizumab + EV group compared to Chemotherapy. The number of patients at risk at different time points is indicated below the x-axis.*

FDA Label Image

Figure 17 (Keytruda Qlex 18)

A Kaplan-Meier survival curve chart comparing overall survival (%) over time in months for two treatment arms: IV Pembrolizumab (solid line) and Chemotherapy (dashed line). The chart shows the number of patients at risk at various time points below the x-axis. Survival rates decrease over 20 months, with intravenous pembrolizumab showing a higher survival percentage than chemotherapy.*

FDA Label Image

Figure 18 (Keytruda Qlex 19)

Kaplan-Meier survival curve showing progression-free survival percentage over time in months for two treatment arms: IV Pembrolizumab (solid black line) and Chemotherapy (dashed gray line). The chart includes a table of number at risk for both groups at various time points up to 48 months.*

FDA Label Image

Figure 19 (Keytruda Qlex 20)

A Kaplan-Meier overall survival curve comparing treatment arms: IV Pembrolizumab plus Standard of Care (SOC) versus SOC alone. The y-axis shows overall survival percentage, and the x-axis shows time in months, with survival decreasing over time. The graph includes numbers at risk for each group at different time points up to 66 months.*

FDA Label Image

Figure 20 (Keytruda Qlex 21)

A Kaplan-Meier survival curve comparing overall survival (%) over time in months for two treatment arms: intravenous pembrolizumab plus chemotherapy and chemotherapy alone. The plot shows higher survival for the pembrolizumab plus chemotherapy group with number at risk tables for each group below the x-axis.*

FDA Label Image

Figure 21 (Keytruda Qlex 22)

A survival curve chart comparing overall survival (%) over time in months for two treatment arms: IV Pembrolizumab plus chemotherapy versus chemotherapy alone. The chart includes number at risk data for each group at various time points up to 50 months.*

FDA Label Image

Figure 22 (Keytruda Qlex 23)

A survival curve chart comparing overall survival percentages over a period of 36 months for two treatment arms: IV Pembrolizumab plus standard of care (SOC) and SOC alone. The chart shows survival decreasing over time with the IV Pembrolizumab+SOC arm consistently above the SOC arm, indicating higher survival rates. A risk table below indicates patient numbers at various time points for each treatment group.*

FDA Label Image

Figure 23 (Keytruda Qlex 24)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months comparing two treatment arms: IV Pembrolizumab plus standard of care (SOC) and SOC alone. The chart includes a risk table indicating the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 24 (Keytruda Qlex 25)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months. It compares two treatment arms: IV Pembrolizumab (solid line) and a control group (dashed line). The chart includes a numeric table below indicating the number of patients at risk across the study duration for each group.*

FDA Label Image

Figure 25 (Keytruda Qlex 26)

A Kaplan-Meier survival curve showing overall survival percentage over time in months. The graph compares a treatment arm with pembrolizumab plus CRT versus CRT alone, with survival percentage on the vertical axis and time in months on the horizontal axis. A table below the graph lists the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 26 (Keytruda Qlex 27)

A Kaplan-Meier progression-free survival curve comparing two treatment arms: IV Pembrolizumab plus CRT (solid black line) and CRT alone (dashed gray line). The y-axis shows progression-free survival percentage, and the x-axis shows time in months up to 30 months. A table below the graph lists the number of patients at risk over time for each group.*

FDA Label Image

Figure 27 (Keytruda Qlex 28)

A Kaplan-Meier survival curve showing overall survival percentage over time in months for two treatment arms: IV Pembrolizumab plus Chemotherapy and Chemotherapy alone. The graph depicts higher survival with the combination treatment compared to chemotherapy alone, with the number of patients at risk listed below corresponding time points.*

FDA Label Image

Figure 28 (Keytruda Qlex 29)

A Kaplan-Meier survival curve chart comparing overall survival (%) over time in months for two treatment arms: IV Pembrolizumab (solid line) and Placebo (dashed line). The chart includes a number at risk table below the x-axis showing patient counts at various time points for each group.*

FDA Label Image

Figure 29 (Keytruda Qlex 30)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months. It compares two treatment arms: IV Pembrolizumab plus chemotherapy (solid line) and placebo plus chemotherapy (dashed line). The chart includes a table of the number of patients at risk for each group at multiple time points up to 40 months.*

FDA Label Image

Figure 30 (Keytruda Qlex 31)

A survival curve chart showing overall survival (%) over time in months, comparing treatment arms: IV Pembrolizumab plus Axitinib (solid line) versus Sunitinib (dashed line). The chart includes data points and a table of numbers at risk for both treatment groups at various time intervals up to 54 months.*

FDA Label Image

Figure 31 (Keytruda Qlex 32)

A Kaplan-Meier progression-free survival curve comparing two treatment arms over approximately 38 months. The y-axis shows progression-free survival percentage, and the x-axis indicates time in months. The black line represents IV Pembrolizumab plus Lenvatinib, showing higher survival, while the gray line represents Sunitinib with lower survival. A risk table beneath lists the numbers at risk for each treatment group over time.*

FDA Label Image

Figure 32 (Keytruda Qlex 33)

A Kaplan-Meier overall survival curve comparing two treatment arms: IV Pembrolizumab + Lenvatinib (solid line) and Sunitinib (dashed line) over 66 months. The graph shows survival percentages on the y-axis and time in months on the x-axis. A table below lists the number of patients at risk for each treatment at various time points.*

FDA Label Image

Figure 33 (Keytruda Qlex 34)

A Kaplan-Meier survival curve chart showing disease-free survival (%) over time in months for two treatment arms: IV Pembrolizumab versus placebo. The chart includes stepwise survival curves and a table of numbers at risk at various time points for both groups.*

FDA Label Image

Figure 34 (Keytruda Qlex 35)

Kaplan-Meier survival curve showing overall survival percentage over time in months. The graph compares two treatment arms: IV Pembrolizumab (solid line) and Placebo (dashed line). A table below the x-axis displays the number of patients at risk in each group at various time points up to approximately 75 months.*

FDA Label Image

Figure 35 (Keytruda Qlex 36)

A Kaplan-Meier survival curve chart showing progression-free survival (%) over time in months. It compares two treatment arms: IV Pembrolizumab plus chemotherapy (paclitaxel and carboplatin) and chemotherapy alone. The chart includes the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure 36 (Keytruda Qlex 37)

A Kaplan-Meier survival curve chart depicting progression-free survival (%) over time in months for two treatment arms: IV Pembrolizumab plus chemotherapy and chemotherapy alone. The chart shows survival proportions with time intervals up to 36 months and includes a risk table with patient counts at various time points for each arm.*

FDA Label Image

Figure 37 (Keytruda Qlex 38)

A Kaplan-Meier survival curve chart showing overall survival percentage over time in months for two treatment arms: IV Pembrolizumab + Lenvatinib (solid line) and Chemotherapy (dashed line). The graph includes risk table counts at intervals below the x-axis, illustrating higher survival rates for the Pembrolizumab + Lenvatinib group compared to chemotherapy over approximately 27 months.*

FDA Label Image

Figure 38 (Keytruda Qlex 39)

A Kaplan-Meier curve graph depicting progression-free survival (%) over time in months. It compares two treatment arms: intravenous Pembrolizumab with Lenvatinib (solid line) versus chemotherapy (dashed line). The graph includes a risk table showing numbers of patients at risk at various time points up to 27 months.*

FDA Label Image

Figure 39 (Keytruda Qlex 40)

A Kaplan-Meier survival curve chart depicting event-free survival (%) over time in months up to 51 months. It compares two treatment arms: IV Pembrolizumab plus chemotherapy and IV Pembrolizumab, and placebo plus chemotherapy/placebo. The chart includes patient risk numbers at various time points for both groups.*

FDA Label Image

Figure 40 (Keytruda Qlex 41)

A Kaplan-Meier survival curve depicting overall survival (%) over time in months comparing two treatment arms: IV Pembrolizumab + Chemo and Placebo + Chemo. The graph includes patient numbers at risk below the X-axis, with two lines showing survival trends for each treatment group.*

FDA Label Image

Figure 41 (Keytruda Qlex 42)

A Kaplan-Meier survival curve graph depicting overall survival percentage over time in months. The graph compares two treatment arms: IV Pembrolizumab plus chemotherapy versus Placebo plus chemotherapy. The number of patients at risk is shown below the x-axis for each group at multiple time points up to 54 months.*

FDA Label Image

Figure 42 (Keytruda Qlex 43)

A Kaplan-Meier survival curve chart displaying progression-free survival percentage over time in months. Two treatment arms are compared: IV Pembrolizumab with chemotherapy (solid line) and placebo with chemotherapy (dashed line). The chart includes a table of numbers at risk for each group across the study duration up to 36 months.*

FDA Label Image

Principal Display Panel (395 mg and 4,800 units/2.4 mL Vial Carton)

Packaging label for Keytruda Qlex injection, containing pembrolizumab and berahyaluronidase alfa-pmph. The label states a strength of 395 mg and 4,800 units per 2.4 mL (165 mg/mL and 2,000 units/mL). It indicates for subcutaneous use only with administration over one minute. Labeler is Merck Sharp & Dohme LLC, with manufacturing information including BSP Pharmaceuticals S.p.A., Italy.*

FDA Label Image

Principal Display Panel (790 mg and 9,600 units/4.8 mL Vial Carton)

Box packaging label for Keytruda Qlex injection, containing pembrolizumab and berahyaluronidase alfa-pmph. The label shows the strength as 790 mg and 9,600 units per 4.8 mL solution (165 mg and 2,000 units/mL). It specifies subcutaneous use with instructions to administer over 2 minutes. The manufacturer is Merck Sharp & Dohme LLC, with the product made in Italy by BSP Pharmaceuticals S.p.A.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.